Vera Therapeutics, Inc.
SEC CIK 1831828 · VERA · last insider filing 2026-06-24
Directors (from insider filings)
| Name | Capacity as filed | Filings |
|---|---|---|
| Fordyce Marshall | Director · President and CEO | filed 2021 - 2026 |
| Seidenberg Beth C | Director | filed 2021 - 2026 |
| Morrissey Michael M | Director | filed 2022 - 2026 |
| Enright Patrick G | Director | filed 2021 - 2026 |
| Meyers James R | Director | filed 2025 - 2026 |
| Morrison Scott W | Director | filed 2021 - 2026 |
| Cheng Andrew | Director | filed 2021 - 2026 |
| Oliger Christy J. | Director | filed 2024 - 2026 |
| Hall Kimball | Director | filed 2021 - 2026 |
| Hite Christopher | Director | filed 2026 - 2026 |
| Katabi Maha | Director | filed 2021 - 2025 |
| Emster Kurt VON | Director | filed 2021 - 2021 |
Officers (from insider filings)
| Name | Title as filed | Filings |
|---|---|---|
| Wright-Mitchell Jane | Chief Legal Officer | filed 2026 - 2026 |
| Young Joseph R | SVP, Finance, Chief Acct Offcr | filed 2021 - 2026 |
| Johnson David LEE | Chief Operating Officer | filed 2024 - 2026 |
| Turner William D. | Chief Regulatory Officer | filed 2024 - 2026 |
| Grant Sean | Chief Financial Officer | filed 2021 - 2026 |
| Brenner Robert | Chief Medical Officer | filed 2024 - 2026 |
| Skelton Laurence Matthew | Chief Commercial Officer | filed 2026 - 2026 |
| Carter Jason S | Chief Legal Officer | filed 2024 - 2025 |
| Curley Joanne | Chief Development Officer | filed 2021 - 2023 |
| Lin Celia | Chief Medical Officer | filed 2021 - 2023 |
| Wolter Jonathan | Chief Financial Officer | filed 2021 - 2021 |
About this record
From the SEC's insider-transaction filings (Forms 3, 4 and 5). Every reporting director and officer carries a Commission-assigned identifier (CIK), so these footprints are identifier-verified - no name matching involved. Insiders file when they transact, so dates are filing dates: "last filed" never means "served until". This layer is not yet joined to the nonprofit register - identity joins ship only after independent review.
Source: SEC Insider Transactions Data Sets (Forms 3/4/5), US Federal Government public domain.